A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP,MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISMSPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION

Project: Research project

Project Details

Description

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISM SPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION
StatusActive
Effective start/end date4/11/184/30/23

Funding

  • HOFFMANN-LA ROCHE PHARMACEUTICALS

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.